CompletedNot Applicable

Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation

United States3,598 participantsStarted 2025-10-31

Plain-language summary

This real-world retrospective study will use de-identified administrative claims data and will examine patients with a diagnosis of COPD who have experienced a qualifying severe disease exacerbation and received subsequent treatment with BGF. Agreed COPD patient data from the Inovalon MORE2 Registry® and Centers for Medicare \& Medicaid Services (CMS) 100% Medicare Fee for Service (FFS) database spanning from January 1, 2021 to the most recently available data (September 30th, 2024 for the MORE2 database, and December 31st, 2023 for the Medicare FFS database) will be used for this analysis. All patients will be required to present at least one prescription claim for BGF. Patients will also be required to show evidence of a qualifying severe COPD exacerbation event during the 180-day period preceding initiation of BGF. Index date will be set as the date of discharge from the qualifying severe exacerbation event.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥ 1 prescription(s) fill for BGF on or following January 1, 2021 * Patients must have evidence of a severe qualifying exacerbation event. * The qualifying severe exacerbation event discharge date must occur within the 180-day period preceding the initiation of BGF for classification of patients into prompt or delayed initiators of BGF. * The discharge date of the first (earliest) observed qualifying index exacerbation event will be set as the index date * ≥ 12 months of continuous health plan enrollment preceding the qualifying index exacerbation event date (baseline period) * ≥ 1 day of continuous enrollment following the qualifying index exacerbation date * Age ≥ 40 years on the qualifying index exacerbation date Exclusion Criteria: * Presence of cancer diagnoses other than basal or squamous cell skin cancer during the baseline period preceding the index date or entire follow-up period * Presence of ≥2 claims with a diagnosis of interstitial fibrosis or sarcoidosis diagnoses during the period preceding the index date or entire follow-up period * Presence of SITT at any time during the entire available history of patients' data preceding the index date through BGF initiation

What they're measuring

Annualized COPD Exacerbation Event Rate

Timeframe: 180 days

Trial details

NCT IDNCT07414134

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-11-28